$49 per month*
Subscribe to Pro or Enterprise plans to unlock this feature.
Become a smarter investor today.
Become a smarter investor today.
This statistic highlights Biocryst Pharmaceuticals’ Revenue by Product Line, split across ORLADEYO, PERAMIVIR and RAPIVAB, reported on a quarterly basis.
|Revenue by Product Line||Q3 2020||Q2 2021||Q3 2021||Contribution in Q3 2021|
(all figures are in millions, except percentages)
The company has 3 major product categories from which it derives its revenue. In Q3 2021, the company’s total revenue stood at $39.14 million. The total revenue in Q3 2021 saw a growth of 17.08% from the previous quarter, wherein the company collected revenue totalling to $33.43 million. As compared to the Q3 2020, the company multiplied its revenue manifold in Q3 2021. In Q3 2020, the company managed to collect $0.296 million in revenue. On a yearly basis, the revenue increased by 13,122%.
The Sales of ORLADEYO prove to be the Company’s principal source of revenue. ORLADEYO is approved in the U.S., the European Union, Japan, the United Kingdom, and the United Arab Emirates for the prevention of HAE attacks in pediatric patients who are 12 years and older. The company started shipping ORLADEYO to its customers in December 2020.
Targeting a new customer base, the company sold $28.37 million worth Orladeyo in Q2 2021. This product held a huge potential and in Q3 2021, Orladeyo again possessed a huge chunk of total revenue. In Q3 2021, the company projected $36.71 million in revenue by selling Orladeyo. This constituted 93.79% of the total revenue earned by the company in all the major product category. In Q3 2021, the sales of Orladeyo grew by 29.4% from the previous quarter. Since, Orladeyo got approval in around December, no sales were recorded in Q3 2020.
Prior to December 2020, the peramivir used to be the only product line from which the company pulled its revenue. But as of now, holds no share in the total revenue of the company. In Q3 2021, the company shifted its focus entirely towards the sale of Orladeyo along with one more product line. In Q2 2021, the company made $0.434 million in revenue by this product line. In Q3 2020, while being the only major product line, the company pulled out $0.296 in revenue from Peramivir. From Q3 2020 to Q2 2021, the revenue from this product line increased by 46.62%.
Along with Orladeyo, the company got approval for Rapivab also. Rapivab is approved in the U.S. for the treatment of acute influenza for patients who are six months and older. It is also approved in Canada and Australia, Japan, Taiwan, and Korea under many distinct names.
In Q3 2021, this product line projected a sales of $2.43 million. This constituted 6.21% of the total sales. In this quarter, the sales of Rapivab saw decline of 47.4% from the previous quarter. In Q2 2021, revenue from this product line amounted to $4.62 million. Since, Rapivab got approval in around December, no sales were recorded in Q3 2020. The company used to sell Rapivab to the Department of Health and Human Services of the U.S under the contract of the Company’s procurement.
Biocryst Pharmaceuticals’ is an America-based commercial-stage biotechnology company having its headquarter in Durham, North Carolina. The company is into discovering novel, oral, small-molecule medicines. The company focuses on oral treatment to cater to the unmet medical needs that exist for rare diseases. Following the process namely Structure-guided drug design, the company integrates crystallography, computer modeling, disciplines of biology, medicinal chemistry to develop small-molecule pharmaceuticals. The company has several ongoing extensive development programs which include, BCX9930, for the treatment of complement-mediated diseases; BCX9250, for the treatment of Fibrodysplasia ossificans progressiva and Galidesivir, for the treatment of yellow fever and Marburg virus disease. The Company sells its products to specialty pharmacy and the specialty pharmacy subsequently sells to its customers [pharmacy benefit managers, insurance companies, government programs, and group purchasing organizations] which dispenses products to patients.
Did you like Biocryst Pharmaceuticals’ Revenue by Product Line statistic?
Access more such KPI data points and segment financials on thousands of US stocks, with Business Quant.
You can get started here.
Always know what you’ll pay. No hidden costs or surprises.
* Billed annually, local taxes extra.
* Local taxes extra.